To use multimodal assessment (fluorescein angiography [FA], color fundus photography [CFP], and/or spectral domain OCT [SD-OCT]) to reevaluate macular atrophy (MA) and macular neovascularization (MNV) type in the HARBOR trial according to the Consensus on Neovascular AMD Nomenclature criteria; and to determine if there are any associations between baseline demographic factors, ocular characteristics, and/or treatment for neovascular age-related macular degeneration (nAMD) and the development of MA by month 24.
Characteristics That Correlate with Macular Atrophy in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration / G. Staurenghi, M. Cozzi, S. Sadda, L. Hill, S. Gune. - In: OPHTHALMOLOGY RETINA. - ISSN 2468-6530. - 7:4(2023 Apr), pp. 300-306. [10.1016/j.oret.2022.11.002]
Characteristics That Correlate with Macular Atrophy in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration
G. Staurenghi
Primo
;M. CozziSecondo
;
2023
Abstract
To use multimodal assessment (fluorescein angiography [FA], color fundus photography [CFP], and/or spectral domain OCT [SD-OCT]) to reevaluate macular atrophy (MA) and macular neovascularization (MNV) type in the HARBOR trial according to the Consensus on Neovascular AMD Nomenclature criteria; and to determine if there are any associations between baseline demographic factors, ocular characteristics, and/or treatment for neovascular age-related macular degeneration (nAMD) and the development of MA by month 24.File | Dimensione | Formato | |
---|---|---|---|
2023.04 Characteristics that Correlate with Macular Atrophy in Ranibizumab-Treated Patients with Neovascular Age-Related Macular Degeneration.pdf
accesso riservato
Descrizione: Original Article
Tipologia:
Publisher's version/PDF
Dimensione
387.65 kB
Formato
Adobe PDF
|
387.65 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.